Navigation Links
First-of-its-kind study creates new tool for targeted cancer drug development
Date:10/30/2011

PHILADELPHIA, PA (October 30 2011)In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

The enzymes, called kinases, catalyze a wide array of vital biological activities. Unfortunately, they can also act as drivers for many forms of cancer. For this reason, the candidate drugs, called kinase inhibitors, have the potential to act as powerful anti-cancer agents. They can also interfere with normal processes in the body, however, resulting in side effects. With the new library, researchers will be able to analyze the complex interactions of these inhibitors with their targets to develop cancer drugs that block specific kinases responsible for disease while seeking to avoid major side effects. The results from the Fox Chase team's first-of-its-kind study will appear in the November issue of Nature Biotechnology.

"These results have pushed the field closer to finding truly specific inhibitors of the processes that drive cancer," says Jeffrey R. Peterson, Ph.D., associate professor in the Cancer Biology Program at Fox Chase and senior author on the new study. "We now have a collection of kinase inhibitors that are more well-characterized and understood than any other library. The next step is to use this information to identify specific, effective therapies that stop cancer in its tracks while avoiding healthy processes."

Already, some cancer patients receive kinase inhibitors to treat their disease, and many more such drugs are being developed, says Peterson. But the body contains more than 500 differ
'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Pediatric personalized medicine takes center stage at first-of-its-kind international conference
2. Mount Sinai Medical Center and ENT & Allergy Associates, LLP Create First-Of-Its-Kind Physician Portal
3. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
4. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
5. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
6. TV drama can be more persuasive than news program, study finds
7. Study carried out into biological risks of eating reptiles
8. Neuroimaging study may pave way for effective Alzheimers treatments
9. Study finds racial gaps continue in heart disease awareness
10. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
11. First blinded study of venous insufficiency prevalence in MS shows promising results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 All on Four dental ... persons who have received dental implants to vigilant in ... post. , The post, which can be found at ... if they don’t brush and floss diligently, they could ... their natural teeth: the bone will deteriorate and the ...
(Date:9/30/2014)... 2014 Youth Town’s annual BBQ/Music Festival ... to 2 p.m. at the Youth Town campus (3641 ... sponsors this family-oriented festival, which will offer music, food ... feature a car show, arts and crafts fair, music, ... games. Also, Lightning McQueen and Mater from the hit ...
(Date:9/30/2014)... 2014 “Biology and botany are ... Brickner, “and it’s about naming rights.” , In ... new on the Bryan William Brickner Blog, the ... Institutes of Health (PubMed). The post highlights five ... REM transitions, aging with THC, the wake-inducing effects ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Top10inaction.com, ... main focus on ranking and reviewing all essential categories ... has officially announced the best liquid foundation at ... Serum Foundation is named as the best foundation of ... drugstore as well as high end brands, hence customers ...
(Date:9/30/2014)... East Longmeadow, Massachusetts (PRWEB) September 30, 2014 ... Excellence’, the Wingate of East Longmeadow facility has ... new Ventilator Program that combines advanced ... staff. This program is one of the only ... this type of care. The primary focus ...
Breaking Medicine News(10 mins):Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3
... mobile computing and medication carts unveils TX11: a mobile computing cart ... ... OH (PRWEB) November 11, 2008 -- The Columbus, OH based medical ... newest in their line of mobile computing carts : the ...
... MOUNTAIN VIEW, Calif., Nov. 11 The 2008 ... Product,Innovation of the Year Award is presented to ... suppressant ingredient -,Slimaluma - for the global weight ... action, superior quality and safety,standards of Slimaluma have ...
... 10 Ready or not, the holiday season,is here. ... turkey and pies, merry-making eggnog and potato latkes,and then ... come Super Bowl,buffalo wings and Valentine,s Day chocolates to ... non-stop holiday cooking and,feasting., Enter Helene Phillips, the ...
... Nov. 10 TeamHealth Inc.,s parent,company, Team Finance ... quarter ended September 30, 2008., The Company ... services business line and substantially completed the disposal,of ... 2007. In accordance with,relevant accounting guidance, the results ...
... Of $9 million appropriated by,the Texas legislature to ... automated external defibrillators (AEDs), $3.5 million remains,unclaimed. Texas ... purchase under,the reimbursement program until the November 14, ... by lay people with CPR training,to resuscitate victims ...
... Increased risk of stroke a major issue in analysis of ... An analysis of 33 studies on drugs known as beta ... surgical procedure other than heart surgery. In fact, using beta ... stroke, the scientists say. , The researchers who conducted the ...
Cached Medicine News:Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 3Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 2Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9Health News:$3.5 Million in Reimbursements for Purchases of Automated External Defibrillators (AEDs) for Texas Schools Still Unclaimed With Deadline Approaching 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3
(Date:9/30/2014)... 2014  Come fall, many children, teenagers, and even ... want to be for Halloween. And, a number of ... contact lenses bought without a prescription. Halloween, ... purchase and wear contact lenses without a prescription. According ... consumer survey, 17 percent of Americans have worn ...
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... and DUBLIN , Sept. ... or the "Company"), a biotechnology company pioneering the manufacturing ... of innovative therapies for cancer, HIV/AIDS, opportunistic infections and ... its shareholders from CEO Noreen Griffin The letter follows: ... (the "Company" or "TNIB") received a number of calls ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 15 Tolerx, Inc., a,biopharmaceutical company engaged in ... treatment of immune-mediated diseases, announced today,the successful completion ... a novel,humanized anti-CD4 monoclonal antibody (MAb), in subjects ... study was designed to,assess the safety, tolerability, and ...
... System Runs ,Heart Model of the Future, ... To Insight, SUNNYVALE, Calif., Jan. 15 In the quest ... Montreal (UdM) have run the largest mathematical simulation of a heart,ever ... system from SGI (Nasdaq: SGIC ). The new UdM model ...
Cached Medicine Technology:Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 2Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 2Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 4
0.25 mm diameter textured tip with protective guard....
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: